The TCGA cohort demonstrated that patients within the CMS4 subtype with low tumour expression of TFF3 exhibited a greater 10-year overall survival outcome compared to patients with high tumour expression of TFF3 (Figure S1A). The gene discussed is TFF3; the disease is neoplasm.